Start-up Workshop Panelist
Dave Garman
Chief Technology Officer, NoNO Inc.
NoNO Inc. is a clinical-stage biotherapeutics company dedicated to the research and development of pharmaceuticals for the treatment of common health disorders with unmet needs, including acute ischemic stroke. The lead therapeutic compound, nerinetide, is a 20 amino acid peptide intended for intravenous infusion to improve patient outcomes for people who have experienced an acute ischemic stroke. Hospitals in the US alone treat approximately 800,000 strokes per year, of which only about 10% ever return to life as it was before. In the global Phase 3 ESCAPE-NA1 study of 1105 participants, when compared to placebo in people experiencing an acute ischemic stroke and patients not receiving alteplase, a single dose of nerinetide given within 12 hours of symptom onset improved functional independence at 90 days by almost 20%, reduced infarct volume by 22% and lowered mortality by 40%. NoNO is currently completing the pivotal Phase 3 ESCAPE-NEXT study as well as the pre-hospital FRONTIER study for suspected stroke.
Dave Garman is currently the Chief Technology Officer for NoNO Inc, a biotechnology company directed at the development of novel peptide therapeutics to treat neurological disorders with unmet medical needs. His roles have encompassed most aspects of the development of a peptide therapeutic for the treatment of stroke from initial animal studies in the laboratory through global Phase 3 clinical trials. Dr. Garman’s primary responsibilities include all aspects of manufacturing and regulatory interactions related to CMC, preclinical safety pharmacology and toxicity assessment of peptide therapeutics, intellectual property and the development of both next generation and novel peptide therapeutics for the company pipeline